DE60305058D1 - Imidazoquinoline derivate als adenosine a3 rezeptor liganden - Google Patents

Imidazoquinoline derivate als adenosine a3 rezeptor liganden

Info

Publication number
DE60305058D1
DE60305058D1 DE60305058T DE60305058T DE60305058D1 DE 60305058 D1 DE60305058 D1 DE 60305058D1 DE 60305058 T DE60305058 T DE 60305058T DE 60305058 T DE60305058 T DE 60305058T DE 60305058 D1 DE60305058 D1 DE 60305058D1
Authority
DE
Germany
Prior art keywords
adenosine
receptor ligands
imidazoquinoline derivatives
imidazoquinoline
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60305058T
Other languages
English (en)
Other versions
DE60305058T2 (de
Inventor
Peter Aranyi
Laszlo Balazs
Maria Balogh
Sandor Batori
Nagy Lajos T
Geza Timari
Kinga Boer
Zoltan Kapui
Endre Mikus
Katalin Gerber
Szeredi Judit Vargane
Katalin Urban-Szabo
Erzsebet Walcz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of DE60305058D1 publication Critical patent/DE60305058D1/de
Application granted granted Critical
Publication of DE60305058T2 publication Critical patent/DE60305058T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
DE60305058T 2002-11-15 2003-11-11 Imidazoquinoline derivate als adenosine a3 rezeptor liganden Expired - Lifetime DE60305058T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU0203976 2002-11-15
HU0203976A HUP0203976A3 (en) 2002-11-15 2002-11-15 Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them
PCT/HU2003/000095 WO2004046146A1 (en) 2002-11-15 2003-11-11 Imidazoquinoline derivatives as adenosine a3 receptor ligands

Publications (2)

Publication Number Publication Date
DE60305058D1 true DE60305058D1 (de) 2006-06-08
DE60305058T2 DE60305058T2 (de) 2006-12-14

Family

ID=90001561

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60305058T Expired - Lifetime DE60305058T2 (de) 2002-11-15 2003-11-11 Imidazoquinoline derivate als adenosine a3 rezeptor liganden

Country Status (35)

Country Link
US (2) US7419977B2 (de)
EP (1) EP1560828B9 (de)
JP (1) JP4533148B2 (de)
KR (1) KR20050088291A (de)
CN (1) CN1332960C (de)
AR (1) AR041968A1 (de)
AT (1) ATE325123T1 (de)
AU (1) AU2003282263B2 (de)
BR (1) BR0316355A (de)
CA (1) CA2505910C (de)
CO (1) CO5690577A2 (de)
CY (1) CY1105180T1 (de)
DE (1) DE60305058T2 (de)
DK (1) DK1560828T3 (de)
EA (1) EA007595B1 (de)
ES (1) ES2263039T3 (de)
HK (1) HK1077819A1 (de)
HR (1) HRP20050540A2 (de)
HU (1) HUP0203976A3 (de)
IL (1) IL168516A (de)
IS (1) IS2456B (de)
MA (1) MA27501A1 (de)
ME (1) MEP19008A (de)
MX (1) MXPA05005198A (de)
NO (1) NO20052866L (de)
NZ (1) NZ540029A (de)
PL (1) PL376837A1 (de)
PT (1) PT1560828E (de)
RS (1) RS51320B (de)
SI (1) SI1560828T1 (de)
TN (1) TNSN05133A1 (de)
TW (1) TWI248934B (de)
UA (1) UA78889C2 (de)
WO (1) WO2004046146A1 (de)
ZA (1) ZA200503807B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0105406A3 (en) * 2001-12-21 2003-12-29 Sanofi Aventis Imidazo[1,2-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
HUP0203976A3 (en) * 2002-11-15 2004-08-30 Sanofi Aventis Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them
HUP0400812A2 (en) * 2004-04-19 2006-02-28 Sanofi Aventis Crystalline forms of 2-amino-3-cyano-quinoline derivatives, process for their preparation and pharmaceutical compositions containing them
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
US20090088403A1 (en) * 2007-05-07 2009-04-02 Randy Blakely A3 adenosine receptors as targets for the modulation of central serotonergic signaling
HUP0700395A2 (en) * 2007-06-07 2009-03-02 Sanofi Aventis Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates
EP2456419B1 (de) 2009-07-21 2016-11-23 Oradin Pharmaceutical Ltd. A3 adenosine rezeptor liganden zur modulation der pigmentierung
EP2950649B1 (de) 2013-02-01 2020-03-04 Wellstat Therapeutics Corporation Aminverbindungen mit entzündungshemmender, fungizider, antiparasitärer und antikrebs-wirkung
KR101820909B1 (ko) * 2017-07-07 2018-01-23 퓨쳐메디신 주식회사 아데노신 유도체를 포함하는 만성신장질환 예방 및 치료용 약학적 조성물
MA50250A (fr) 2017-09-15 2020-07-22 Forma Therapeutics Inc Compositions de tétrahydroimidazo quinoléine utilisées en tant qu'inhibiteurs de cbp/p300
BR112020026783A2 (pt) 2018-06-29 2021-03-30 Forma Therapeutics, Inc. Inibição da proteína de ligação creb (cbp)
BR112021016921A2 (pt) * 2019-03-15 2021-11-03 Forma Therapeutics Inc Inibição de proteína de ligação a elemento responsivo a amp cíclico (creb)
US11795168B2 (en) 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4075343A (en) * 1976-09-13 1978-02-21 Pfizer Inc. Anti-allergenic 5-alkoxyimidazo[1,2-A]quinoline-2-carboxylic acids and derivatives thereof
GB1596652A (en) * 1977-01-20 1981-08-26 Roussel Lab Ltd Imidazo (1,2-a) quinoline-2-carboxylic acid and derivatives
US4644002A (en) * 1979-02-09 1987-02-17 Roussel Uclaf Imidazo[2,1-C]quinolines, useful as antiallergic agents
IL59104A (en) * 1979-02-09 1984-02-29 Roussel Uclaf Heterotricyclic derivatives,process for their preparation and pharmaceutical compositions incorporating them
FR2448541A1 (fr) * 1979-02-09 1980-09-05 Roussel Uclaf Nouveaux derives de l'oxoimidazoquinoxaline et leurs sels, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
CA2336967C (en) * 1998-07-10 2010-06-29 The United States Of America, Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor antagonists
US6448253B1 (en) * 1998-09-16 2002-09-10 King Pharmaceuticals Research And Development, Inc. Adenosine A3 receptor modulators
KR20020046285A (ko) * 1999-09-28 2002-06-20 고마즈 교우이찌 트리아조로푸린 유도체,그 유도체를 함유하는 의약 조성물및 아데노신 에이 3 수용체 친화제
US7160890B2 (en) * 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
WO2002057267A1 (en) * 2000-12-01 2002-07-25 Osi Pharmaceuticals, Inc. Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof
RS95003A (en) * 2001-05-31 2007-02-05 Sanofi-Aventis, Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands
HUP0105407A3 (en) * 2001-12-21 2004-04-28 Sanofi Aventis Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
HUP0105406A3 (en) * 2001-12-21 2003-12-29 Sanofi Aventis Imidazo[1,2-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
HUP0203976A3 (en) * 2002-11-15 2004-08-30 Sanofi Aventis Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
EP1560828B1 (de) 2006-05-03
IS7874A (is) 2005-05-31
KR20050088291A (ko) 2005-09-05
IS2456B (is) 2008-11-15
WO2004046146A1 (en) 2004-06-03
HRP20050540A2 (en) 2005-08-31
TWI248934B (en) 2006-02-11
RS20050364A (en) 2007-08-03
CO5690577A2 (es) 2006-10-31
HUP0203976A2 (hu) 2004-07-28
PT1560828E (pt) 2006-08-31
US20050234056A1 (en) 2005-10-20
US20080255110A1 (en) 2008-10-16
ES2263039T3 (es) 2006-12-01
JP2006515572A (ja) 2006-06-01
CN1726213A (zh) 2006-01-25
PL376837A1 (pl) 2006-01-09
UA78889C2 (en) 2007-04-25
NZ540029A (en) 2007-01-26
EP1560828A1 (de) 2005-08-10
US7419977B2 (en) 2008-09-02
JP4533148B2 (ja) 2010-09-01
SI1560828T1 (sl) 2006-08-31
AU2003282263A1 (en) 2004-06-15
HU0203976D0 (en) 2003-01-28
IL168516A (en) 2011-05-31
RS51320B (sr) 2010-12-31
CY1105180T1 (el) 2010-03-03
HK1077819A1 (en) 2006-02-24
BR0316355A (pt) 2005-09-27
CN1332960C (zh) 2007-08-22
EA007595B1 (ru) 2006-12-29
EP1560828B9 (de) 2007-02-14
DE60305058T2 (de) 2006-12-14
TW200413369A (en) 2004-08-01
EA200500830A1 (ru) 2005-10-27
MXPA05005198A (es) 2005-08-18
US7709489B2 (en) 2010-05-04
ZA200503807B (en) 2006-08-30
TNSN05133A1 (en) 2007-05-14
CA2505910C (en) 2010-07-13
CA2505910A1 (en) 2004-06-03
AU2003282263B2 (en) 2009-05-14
AR041968A1 (es) 2005-06-01
NO20052866D0 (no) 2005-06-13
DK1560828T3 (da) 2006-09-04
HUP0203976A3 (en) 2004-08-30
MA27501A1 (fr) 2005-08-01
ATE325123T1 (de) 2006-06-15
NO20052866L (no) 2005-06-13
MEP19008A (en) 2010-06-10

Similar Documents

Publication Publication Date Title
ATE450528T1 (de) Chinazolinderivate als antitumormittel
ATE384053T1 (de) Triazolderivate als tachykininrezeptor- antagonisten
DK1611131T3 (da) Pyrazolopyridin-derivater
ATE359275T1 (de) Substituierte bizyclische derivate verwendbar als antitumor mittel
ATE512965T1 (de) Pyrrolopyrimidin derivate
DE60331444D1 (de) 1h-1,2,4- triazol-3- carboxamid derivate als cannabinoid-cb1 receptor liganden
NO20052866D0 (no) Imidazokinolinderivater som adenosin A3 reseptorligander
ATE415400T1 (de) Pyrazolopyridinderivate
DE60207815D1 (de) 1-aryl-oder 1-alkylsulfonylbenzazol derivate als 5-hydroxytryptamin-6 liganden
ATE340782T1 (de) Piperidinbenzolsulfonamidderivate
DE60317102D1 (de) Pyrrolopyridazin derivate
MA28686B1 (fr) Derives de pyrrolopyridine
ATE352550T1 (de) Chinazolinderivate
ATE386518T1 (de) Benzimidazolderivate
ATE452892T1 (de) Substituierte 8-perfluoro-6,7,8,9- tetrahydropyrimido-(1,2a) pyrimidin-4-on derivate
ATE398450T1 (de) Derivate von aryl-chinazolin/aryl-2amino-phenyl- methanon zurförderung der freisetzung von parathormon
ATE306265T1 (de) Benzothiazolderivate als adenosin-rezeptor- liganden
ATE377008T1 (de) Imidazolderivate als glutamatrezeptorantagonisten
DE60316411D1 (de) Thiazolderivate als npy-rezeptorantagonisten
ATE354365T1 (de) N-thiazol-2-yl-benzamid-derivate
ATE394372T1 (de) G-lactamderivate als prostaglandinagonisten
ATE281456T1 (de) Aminotriazolopyridinderivate als adenosinrezeptorliganden
ATE338043T1 (de) 5-methoxy-8-aryl- 1,2,4ötriazolo 1,5-aöpyridine derivative als adenosin-rezeptor antagonisten
DK1636223T3 (da) Benzothiazolderivater som adenosinreceptorligander
ATE495168T1 (de) Heteroarylsubstituierte imidazolderivate als glutamatrezeptorantagonisten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition